Connect your AI

Biohaven BHVN Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Xenon PharmaceuticalsXENE

-$103.85M-61.6%

Rapport Therapeutics, Inc.RAPP

-$20.91M+11.5%

uniQureQURE

-$55.2M-23.6%

Monte Rosa Therapeutics, Inc.GLUE

-$45.42M-197%

AnaptysBio, Inc.ANAB

-$53.01M-34.3%

Viridian Therapeutics, Inc.VRDN

-$105.91M-22.2%

Other financials

Income statement

Operating income-$130.4M+41.1%

Net income-$130.5M+41.1%

EPS (diluted)-$0.88+59.4%

Balance sheet

Cash & equivalents$277.1M+170%

Total debt$286.2M+706%

Total equity$129.5M-50.1%

Total assets$466.4M+1.6%

Cash flow

Operating cash flow-$149.9M+9.2%

CapEx--100%

Free cash flow-$149.9M+9.5%

Valuation

Market cap$2.25B-48.1%

Enterprise value$2.26B-46.3%

Returns & leverage

Return on equity-333%+17.9pp

Debt / equity2.2×+2.1×

Current ratio7.4×+5.1×

Where this comes from

Reported directly by Biohaven in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Biohaven’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biohaven's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Biohaven's comprehensive income (loss), net of tax, attributable to parent?: Biohaven (BHVN) reported comprehensive income (loss), net of tax, attributable to parent of -$130.58M in Q1 2026.
How has Biohaven's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?: Biohaven's comprehensive income (loss), net of tax, attributable to parent increased by 41.1% year-over-year, from -$221.68M to -$130.58M.